IGNYTE-ESO
IGNYTE-ESO was the pivotal study for the second sarcoma TCR-T, with responses in 42% of patients with two rare sarcomas.
ORR 42% by independent review (41% synovial sarcoma, 43% MRCLS); median DOR 12.2 months overall, 18.3 in synovial sarcoma; cytopenias and CRS as expected. Basis for a BLA due by end-2026 (US WorldMeds).
- 42 out of 100 people had their tumour shrink with Lete-cel.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Advanced synovial sarcoma or myxoid/round cell liposarcoma, NY-ESO-1+, HLA-A*02+: lete-cel (single arm). People in a different situation may not see the same effect.
- Only 64 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares Letetresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- Key paperSPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares Letetresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- CompanyUS WorldMeds
Shares Letetresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- CompanyImmatics
Shares TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- TargetMAGE-A4
Shares TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- InstitutionOslo University Hospital – The Norwegian Radium Hospital
Shares TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- Key paperSPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- TermHLA-A*02:01 restriction
Shares TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).